BioNJ Member Elusys Therapeutics announced it has been awarded $16 million of additional funding from the U.S. Government to further advance development of a lyophilized form of Anthim® (obiltoxaximab), an investigational agent for the treatment of inhalational anthrax infection following a biowarfare attack.
The National Institute of Neurological Disorders and Stroke (NINDS) has awarded BioNJ Member RUCDR Infinite Biologics, a unit of Rutgers’ Human Genetics Institute of New Jersey, a $6 million grant. RUCDR, which is located on Rutgers’ Busch Campus in Piscataway, is the world’s largest university-based biorepository.
In a study involving nearly 400 subjects, researchers from BioNJ Member Rowan University School of Osteopathic Medicine and Durin Technologies, have demonstrated that a blood test they developed can detect early-stage Parkinson’s disease.